EQS-Ad-hoc: BB BIOTECH AG / Schlagwort(e): Jahresbericht Ad hoc-Mitteilung gemäss Art. 53 KR BB Biotech AG veröffentlicht Geschäftsbericht 2022 Die BB Biotech AG hat heute ihren Geschäftsbericht für das Jahr 2022 vorgelegt. Der Bericht enthält neben den geprüften Jahresabschlusszahlen auch ausführliche Informationen zum Biotechnologiesektor sowie zur Positionierung von BB Biotech, den abgedeckten Investmentthemen und den Portfoliopositionen. Der vollständige Geschäftsbericht 2022 der BB Biotech AG ist auf report.bbbiotech.ch/2022/de resp. www.bbbiotech.com verfügbar. Für weitere Informationen: Investor Relations Media Relations TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Schweiz, Tel. +41 79 423 22 28 www.bbbiotech.com Unternehmensprofil Haftungsausschluss
17.02.2023 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. |
Sprache: | Deutsch |
Unternehmen: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Schweiz | |
Telefon: | +41 52 624 08 45 |
E-Mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Börsen: | Regulierter Markt in Frankfurt (Prime Standard); Mailand, SIX |
EQS News ID: | 1561801 |
Ende der Mitteilung | EQS News-Service |
|
1561801 17.02.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.